_1777294237270_124456903.png&w=64&q=75){kind=small}
Jascide approved for adult pulmonary fibrosis
The General Authority for Food and Drug Administration has approved the registration of the medication "Jascaid" (Nirandomilaast) for the treatment of idiopathic pulmonary fibrosis, a rare disease characterized by the accumulation of fibrous scar tissue in the lungs, which leads to shortness of breath and persistent cough. The medication acts as an inhibitor of the phosphodiesterase type 4 (PDE4B) enzyme and works by increasing intracellular levels of cyclic adenosine monophosphate (cAMP) to reduce fibrosis and pulmonary inflammation. Clinical studies have shown that "Jascaid" slows the decline in lung function, with notable reductions in forced vital capacity (FVC) observed after 52 weeks of treatment. Side effects include diarrhea, nausea, and loss of appetite. Its approval follows a thorough evaluation of its efficacy and safety, thus expanding treatment options for rare diseases with limited therapies, as part of the health sector transformation program within Saudi Vision 2030.
Notice: This Is an AI-Generated Summary
Comments (0)